Drug intelligence / Profile preview

SPH1188-11

Development stage: Unknown
Lead developer: Shanghai Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SPH1188-11 is an investigational small molecule drug developed by Shanghai Pharmaceuticals Holding for the treatment of non-small cell lung cancer (NSCLC). It acts as an epidermal growth factor receptor (EGFR) antagonist, targeting tumors that have progressed after prior anti-cancer therapy. The drug was evaluated in a Phase I clinical trial to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with locally advanced or metastatic NSCLC. The highest development status reached was Phase 1; however, the program has been suspended/withdraw/n and no further clinical development is ongoing[1][2][3].

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on SPH1188-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH1188-11.

Explore the full profile